Climb Bio, Inc. Common Stock
CLYMClimb Bio, Inc. (CLYM) is a biotechnology company focused on developing innovative therapies targeting neurodegenerative diseases. The company leverages its proprietary platforms to discover and advance drug candidates aimed at addressing unmet medical needs in neurosciences.
Company News
The idiopathic membranous nephropathy (IMN) market is expected to grow from USD 130 million in 2025 to USD 1 billion by 2036, driven by rising disease prevalence, improved diagnostics, and emerging targeted therapies. Multiple pharmaceutical companies are advancing novel treatments including SNP-ACTH (1-39) Gel, zanubrutinib, obinutuzumab, and po...
Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company, announced that its executive team will participate in three upcoming healthcare and biotech conferences in February and March 2026, including Guggenheim's Emerging Outlook: Biotech Summit, Oppenheimer's 36th Annual Healthcare Life Sciences Conference, and Leerink Global Healt...
Climb Bio granted a non-statutory stock option to a new employee for 120,000 shares at $1.76 per share, vesting over four years with standard stock option terms.
Climb Bio presented preclinical data for CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy, and long-term clinical data for budoprutug, an anti-CD19 monoclonal antibody showing potential in primary membranous nephropathy treatment.
Climb Bio, a clinical-stage biotechnology company, will participate in multiple healthcare investor conferences in September 2025, presenting its pipeline of therapeutics for immune-mediated diseases.
